AbbVie
ABBV
3,323 hedge funds and large institutions have $198B invested in AbbVie in 2023 Q4 according to their latest regulatory filings, with 366 funds opening new positions, 1,172 increasing their positions, 1,424 reducing their positions, and 98 closing their positions.
273% more first-time investments, than exits
New positions opened: 366 | Existing positions closed: 98
85% more call options, than puts
Call options by funds: $4.51B | Put options by funds: $2.44B
8% more capital invested
Capital invested by funds: $183B → $198B (+$14.4B)
7% more funds holding
Funds holding: 3,109 → 3,323 (+214)
2.66% more ownership
Funds ownership: 69.64% → 72.3% (+2.7%)
10% less funds holding in top 10
Funds holding in top 10: 224 → 202 (-22)
18% less repeat investments, than reductions
Existing positions increased: 1,172 | Existing positions reduced: 1,424
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.24B |
| 2 |
BlackRock
New York
|
+$753M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$371M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$348M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$346M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$490M |
| 2 |
JP Morgan Chase
New York
|
-$468M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$379M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
-$244M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$205M |
ABBV Hedge Fund Activity: Q4 2023 in Review
3,323 of the 6,861 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2023, worth a combined $198B — up 7.9% from $183B a quarter earlier.
Buyers outnumbered sellers: 366 funds opened new ABBV positions and 98 closed out — a net gain of 268 holders — while 1,172 added to existing stakes and 1,424 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $5.24B. The largest seller was T. Rowe Price Associates, cutting an estimated $490M.
- 3,323 institutional investors held AbbVie (ABBV) as of Q4 2023, up from 3,109 in Q3 2023.
- Funds reported $198B of AbbVie stock for Q4 2023, up 7.9% quarter-over-quarter.
- 366 funds opened new AbbVie positions in Q4 2023 and 98 closed out, a net change of +268 holders.
- The largest AbbVie buyer in Q4 2023 was Morgan Stanley, an estimated $5.24B added.
- The largest AbbVie seller in Q4 2023 was T. Rowe Price Associates, an estimated $490M sold.
Based on aggregated 13F filings for Q4 2023.